Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device
Authors:
Open Access
- 21 October 2010
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 18 (3) , 258-265
Abstract
The magnitude of the immune response to a DNA vaccine depends on three criteria—the optimized vector design, the use of a suitable adjuvant and the successful delivery and subsequent expression of the plasmid in the target tissue. In vivo electroporation (EP) has proved to be particularly effective in efficiently delivering DNA immunogens to the muscle and the skin, and indeed several devices have entered into human clinical trials. Here, we report on a novel concept of DNA delivery to the dermal tissue using a minimally invasive EP device, which is powered using low-voltage parameters. We show that this prototype device containing a novel 4 × 4-electrode array results in robust and reproducible transfection of dermal tissue and subsequent antigen expression at the injection site. Using DNA encoding for NP and M2e influenza antigens, we further show induction of potent cellular responses in a mouse model as measured by antigen-specific T-cell ELISpot assays. Importantly, 100% of the immunized animals were protected when challenged with VN/1203/04 (H5N1) strain of influenza. We have also extended our findings to a guinea-pig model and demonstrated induction of HI titers greater than 1:40 against a pandemic novel H1N1 virus showing proof of concept efficacy for DNA delivery with the prototype device in a broad spectrum of species and using multiple antigens. Finally, we were able to generate protective HI titers in macaques against the same novel H1N1 strain. Our results suggest that the minimally invasive dermal device may offer a safe, tolerable and efficient method to administer DNA vaccinations in a prophylactic setting, and thus potentially represents an important new option for improved DNA vaccine delivery in vivo.Keywords
This publication has 29 references indexed in Scilit:
- Microneedle Delivery of H5N1 Influenza Virus-Like Particles to the Skin Induces Long-Lasting B- and T-Cell Responses in MiceClinical and Vaccine Immunology, 2010
- Persistent Immune Responses Induced by a Human Immunodeficiency Virus DNA Vaccine Delivered in Association with Electroporation in the Skin of Nonhuman PrimatesHuman Gene Therapy, 2009
- Dendritic cells: biology of the skinContact Dermatitis, 2009
- DNA vaccines: Crossing a line in the sandVaccine, 2008
- Enhanced Cellular Immune Responses Elicited by an Engineered HIV-1 Subtype B Consensus-based Envelope DNA VaccineMolecular Therapy, 2007
- Biochemistry of human skin—our brain on the outsideChemical Society Reviews, 2005
- Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope GlycoproteinJournal of Virology, 2005
- Multiple Effects of Codon Usage Optimization on Expression and Immunogenicity of DNA Candidate Vaccines Encoding the Human Immunodeficiency Virus Type 1 Gag ProteinJournal of Virology, 2001
- Induction of Potent Th1‐Type Immune Responses from a Novel DNA Vaccine for West Nile Virus New York Isolate (WNV‐NY1999)The Journal of Infectious Diseases, 2001
- DNA VACCINESAnnual Review of Immunology, 1997